Background: The 2018 Lipids in Parenteral Nutrition summit involved a panel of experts in clinical nutrition, lipid metabolism, and pharmacology, to assess the current state of knowledge and develop expert consensus statements regarding the use of intravenous lipid emulsions in various patient populations and clinical settings. The main purpose of the consensus statements is to assist healthcare professionals by providing practical guidance on common clinical questions related to the provision of lipid emulsions as part of parenteral nutrition (PN). Methods: The summit was designed to allow interactive discussion and consensus development. The resulting consensus statements represent the collective opinion of the members of the expert panel, which was informed and supported by scientific evidence and clinical experience. Results: The current article summarizes the key discussion topics from the summit and provides a set of consensus statements designed to complement existing evidence-based guidelines. Lipid emulsions are a major component of PN, serving as a condensed source of energy and essential fatty acids. In addition, lipids modulate a variety of biologic functions, including inflammatory and immune responses, coagulation, and cell signaling. A growing body of evidence suggests that lipid emulsions containing ω-3 fatty acids from fish oil confer important clinical benefits via suppression of inflammatory mediators and activation of pathways involved in the resolution of inflammation. Conclusions: This article provides a set of expert consensus statements to complement formal PN guideline recommendations. (JPEN J Parenter Enteral Nutr. 2020;44(suppl S1):S7-S20)
Introduction
The Lipids in Parenteral Nutrition summit was held on November 2-4, 2018, in Miami, Florida, USA. The summit brought together expert clinicians and scientists from 5 continents to evaluate the current state of knowledge and offer practical guidance on the use of intravenous (IV) lipid emulsions in various patient populations and clinical settings, with a particular focus on the role of lipid emulsions containing ω-3 fatty acids. The main goal of the summit was to develop consensus statements to address common clinical questions related to the following 6 topics: (1) biologic effects of lipids, (2) hospitalized adults requiring parenteral nutrition (PN), (3) adults requiring home PN, (4) neonates requiring PN, (5) pediatric patients requiring PN, and (6) practical handling aspects. In addition, because the cost-effectiveness of therapy is an increasingly important topic, pharmacoeconomic considerations were addressed as a separate topic for discussion.
The format of the summit was designed to allow interactive discussion and consensus development. The resulting consensus statements represent the collective opinion of the members of the expert panel, which was informed and supported by scientific evidence and clinical experience. Importantly, the expert panel is not a formal guideline committee or sanctioned voting body. Thus, the consensus statements are not intended to be viewed as formal guidelines, but rather to complement existing evidence-based guidelines and position statements from national and international nutrition societies, thus assisting healthcare professionals by bridging the gap between published guideline recommendations and practical questions that are commonly encountered in routine clinical practice.
The current article summarizes the highlights and consensus statements from the summit. A complete list of consensus statements and corresponding voting results is provided in Table 1 . A more detailed review of the relevant clinical considerations for each topic area can be found in the accompanying articles in the current supplement. 
Topic Consensus Statements
Biological aspects 1. We recognize that lipid emulsions are an integral part of PN. Originally, lipid emulsions were an energy-dense source of calories and provided essential FAs (100% agreement; 16 agree, 0 do not agree, 0 do not wish to answer).
Subsequent generations of lipid emulsions include combinations of various lipid components,
predominantly with the aim of improving the safety profile of ILEs. Each lipid has its own FA composition and biological effects, which may be more or less beneficial on, for example, pro-or anti-inflammatory, immune-stimulating or modulating properties (100% agreement; 17 agree, 0 do not agree, 0 do not wish to answer). 3 . An important component of modern composite lipid emulsions is fish oil. The group recognizes that the biological effects of fish oil are increasingly characterized in preclinical studies (different models). The biological effects of fish oil can mainly be attributed to ω-3 polyunsaturated FAs, especially EPA and DHA, and include anti-inflammatory and immunomodulatory and anti-oxidative properties (94% agreement; 16 agree, 0 do not agree, 1 does not wish to answer). 4. In the view of the group, the latest findings regarding the role of specialized pro-resolution mediators (SPMs) in immune modulation add considerably to our understanding of the biological characteristics of fish oil. 19 . Based on currently available clinical data, there is no need to withhold or limit (for safety concerns) the use of fish-oil containing ILEs for PN during the first week of PN (100% agreement; 16 agree, 0 do not agree, 0 do not wish to answer). 20. Based on clinical studies, systematic reviews and meta-analyses, there is no evidence that fish-oil containing lipids increase the risk of coagulopathy or bleeding abnormalities (100% agreement; 16 agree, 0 do not agree, 0 do not wish to answer). 21 . Serum TG levels should be within the ranges recommended by local or regional guidelines; in general, they should not exceed 400 mg/dL (4.5 mmol/L) during infusion. If the level is high on initial testing, ensure that the blood sample was drawn from an appropriate location. We recommend serum TG levels be measured at the baseline in all patients being considered for PN (100% agreement; 16 agree, 0 do not agree, 0 do not wish to answer). 22. We recommend considering early initiation of PN in low-risk surgical patients if it is anticipated that the patient will be unable to attain 50-60% of goal energy and proteins within the first 5 days (100% agreement; 16 agree, 0 do not agree, 0 do not wish to answer economic outcomes research were invited to participate in an international consensus development conference to address common clinical questions related to the use of lipid emulsions. The overall objective of the conference was to offer practical guidance and expert consensus opinion on the use of lipid emulsions in various patient populations and clinical settings.
Consensus statements were developed using an adapted version of the Delphi technique, a widely used group communication process that aims to achieve a convergence of opinion through the collection of information regarding a specific topic within the participants' domain of expertise. 1 For each topic area, expert presentations summarizing the current state of knowledge and relevant recommendations from existing guidelines were followed by a panel discussion focused on the identification of priority issues and the development of corresponding draft consensus statements. At the conclusion of each round of discussion, panel members were asked to indicate by anonymous vote the degree to which they agreed with each consensus statement by selecting 1 of the following responses: agree, do not agree, or do not wish to answer. Votes were recorded electronically to ensure anonymity. The voting results for each consensus statement are reported as the percentage of agreement, as well as the number of respondents for each of the 3 possible response categories.
A draft manuscript summarizing the key discussion topics and corresponding consensus statements was prepared for each topic area and circulated among the members of the expert panel for review and comment.
Biological Aspects of Lipid Administration
It is now well established that individual fatty acids have unique functional properties; therefore, when prescribing lipid emulsions, it is important to understand the biological properties of the constituent fatty acids. 2 The article by Calder et al 3 in the current supplement highlights evidence from molecular studies that has led to important insights regarding the differential biological effects of individual fatty acids as well as the specific pathways through which these effects are mediated. Consensus statements related to the biological aspects of lipid administration are presented in Table 1 (consensus statements 1-4).
Role of Lipids
Lipid emulsions are an integral component of PN. In addition to serving as an energy-dense source of energy and essential fatty acids (EFAs), lipids facilitate the delivery of lipid-soluble vitamins and modulate several biologic functions, including inflammatory and immune responses, coagulation, and cell signaling. 4, 5 
The Influence of Fatty-Acid Composition on the Biological Effects of Lipid Emulsions
A wide variety of commercial lipid emulsions are now available for use in PN. 4 Soybean oil is the traditional lipid source in IV lipid emulsions 6 ; however, based on concerns that an excessive supply of ω-6 fatty acids might be associated with inflammatory and immunosuppressive effects, subsequent generations of lipid emulsions include lipids derived from alternative oil sources as well as composite lipid emulsions containing a mixture of lipids from different oil sources. 7 Fish oil has become an important component of modern, composite lipid emulsions, owing in part to a growing body of evidence suggesting favorable effects on a variety of key biologic functions. 5, 6 The biological effects of lipid emulsions are strongly influenced by their fatty-acid composition. [4] [5] [6] [7] [8] [9] [10] Pure soybeanoil emulsions contain high concentrations of the ω-6 polyunsaturated fatty acid (PUFA) linoleic acid, which is converted to arachidonic acid, a precursor to eicosanoids that promote inflammation and suppress cell-mediated immunity. 5, 11 In contrast, lipid emulsions containing fish oil are rich in ω-3 PUFAs such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which exhibit anti-inflammatory, immunomodulatory, and antioxidative properties in preclinical models. 4, 5, 12 Medium-chain triglycerides (derived from coconut oil or palm kernel oil) and olive oil are generally regarded as less inflammatory than soybean oil. 4, 8, 13 
Biological Effects of Fish Oil
The recent characterization of a novel superfamily of lipid mediators known as specialized pro-resolving mediators (SPMs) has led to important insights regarding the biological effects of fish oil. SPMs include resolvins, protectins, and maresins. 4, 5, 14 Synthesized directly from the ω-3 fatty acids DHA and EPA, SPMs initiate signaling cascades that activate pathways involved in the resolution of inflammation. 15, 16 Specifically, SPMs promote cessation of leukocyte infiltration, stimulate macrophage uptake of apoptotic cells, and facilitate clearance of cellular debris. 15, 16 In addition, SPMs inhibit the synthesis of inflammatory mediators, including cytokines, adhesion molecules, cyclooxygenase-2, and inducible nitric oxide synthase. 4, 15 Emerging evidence from clinical studies suggests that the biological effects of lipid emulsions containing ω-3 fatty acids confer meaningful clinical benefits, particularly in patients with clinical conditions characterized by a hypermetabolic or hyperinflammatory state. 8, 12 Hospitalized Adults Requiring PN There is a growing body of evidence suggesting that differences in the fatty-acid composition of lipid emulsions can influence clinical outcomes in hospitalized adults who require PN. 17 The article by Mayer et al 18 in the current supplement reviews the evidence from clinical studies evaluating lipid emulsions in adult critically ill and surgical patients and presents consensus statements related to the use of lipid emulsions in hospitalized adults. Consensus statements related to the provision of lipid emulsions to adult critically ill (consensus statements 5-13) and surgical patients (consensus statements 14-25) are presented in Table 1 .
Critically Ill Patients
Role of lipid emulsions in critically ill adults requiring PN. Lipid emulsions are an integral component of nutrition therapy in hemodynamically stable, critically ill adults requiring PN. 19, 20 Lipid emulsions provide a concentrated supply of energy and EFAs, thereby reducing the risks of carbohydrate overload and EFA deficiency. 6 Critical illness is associated with a systemic inflammatory response that markedly increases metabolic demands, leading to an increased risk of infection, increased length of stay in the intensive care unit (ICU), and increased mortality rates. [21] [22] [23] [24] [25] There is evidence that ω-3 fatty acids such as DHA and EPA attenuate the systemic inflammatory response and support immune function. 4, 5 Evidence from studies in critically ill adults suggests that the anti-inflammatory and immunomodulatory properties of ω-3 fatty acids confer significant clinical benefits, including reduced risk of infection, [26] [27] [28] [29] reduced duration of mechanical ventilation, 30, 31 and decreased length of stay in the ICU 29, 31, 32 and in the hospital. 26, 27, 32, 33 Use of Lipid Emulsions Containing Fish Oil in Critically Ill Adults. The results of recently published clinical studies and meta-analyses demonstrate that lipid emulsions containing fish oil are associated with significant clinical benefits compared with standard lipid emulsions (ie, without fish oil) in critically ill adults who require PN. [26] [27] [28] [29] [30] [31] Based on these findings, it is the consensus opinion of the expert panel that there is sufficient scientific evidence to support the use of lipid emulsions containing fish oil in critically ill adult patients requiring PN (consensus statements 6 and 7, Table 1 ).
Certain groups of high-risk patients may benefit from early administration of lipid emulsions containing ω-3 fatty acids, including patients with sepsis, trauma, acute respiratory distress syndrome, and other states of acute stress that can result in conditions such as systemic inflammatory response syndrome (SIRS), compensatory anti-inflammatory response syndrome (CARS), or persistent inflammation, immunosuppression, and catabolism syndrome (PICS). [34] [35] [36] [37] Lipid Requirements in Critically Ill Adults. In critically ill adults, the dose of lipids should be sufficient to prevent EFA deficiency. The total lipid dose should not exceed 1.5 g/kg/d, including lipids from non-nutritive sources such as propofol. 19 Based on clinical data, 38 0.1-0.2 g fish oil/kg/d should be administered as part of the IV lipid emulsion (consensus statement 9, Table 1 ). 4 When using an all-in-one admixture, the preferred duration of infusion is 24 hours (consensus statement 11, Table 1 ).
Monitoring. Serum triglyceride concentrations should be assessed at baseline and monitored routinely throughout the duration of PN therapy. 39 Serum triglyceride levels should be within the ranges recommended by local or regional guidelines, and generally should not exceed 400 mg/dL (4.5 mmol/L) during infusion (consensus statement 10, Table 1 ).
Surgical Patients
Role of lipid emulsions in adult surgical patients requiring PN. In adult surgical patients, the primary indication for PN is intestinal failure, defined as the reduction of gut function below the minimum necessary for the absorption of macronutrients, water, or electrolytes, such that IV supplementation is required to maintain health or normal growth. 40 In surgical patients who require PN, IV lipid emulsions are an integral part of nutrition therapy (consensus statement 14, Table 1 ).
Use of Lipid Emulsions Containing Fish Oil in Adult Surgical Patients.
Evidence from clinical studies and meta-analyses demonstrates that lipid emulsions containing fish oil offer several clinical advantages compared with those containing no fish oil in adult surgical patients, including reduced risk of infectious complications, 28, 29, [41] [42] [43] [44] decreased length of stay in the ICU, 29, 32, 41, 42 and decreased length of stay in the hospital. 28, 29, 32, [42] [43] [44] According to the European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines on clinical nutrition in surgery, postoperative PN including ω-3 fatty acids should be considered only in patients who cannot be adequately fed enterally and thus require PN (grade of recommendation B: majority agreement [65%]). 45 Based on the findings from clinical studies, systematic reviews, and meta-analyses, there is no evidence that lipid emulsions containing fish oil increase the risk of coagulopathy or bleeding abnormalities compared with standard lipid emulsions that do not contain fish oil. 4 Lipid Requirements in Adult Surgical Patients. In adult surgical patients who require PN, the dose of lipids should be sufficient to prevent EFA deficiency. 21 The total lipid dose should not exceed 1.5 g/kg/d, including lipids from nonnutritive sources (consensus statement 17, Table 1 ). Based on clinical data, 38 0.1-0.2 g fish oil/kg/d should be given as part of the lipid emulsion. 4 Monitoring. Consistent with recommendations for patients with critical illness, serum triglyceride levels should be assessed at baseline and monitored routinely throughout the duration of PN therapy. 39 Serum triglyceride levels should be within the ranges recommended by local or regional guidelines, and generally should not exceed 400 mg/dL (4.5 mmol/L) during infusion (consensus statement 21, Table 1 ).
Adults Requiring Home PN
Home PN is a life-saving therapy in adult patients with chronic intestinal failure. 46 However, patients with intestinal failure who require long-term PN are at risk of developing intestinal failure associated liver disease (IFALD). The accompanying article by Mundi et al 47 examines factors that may contribute to IFALD and discusses lipid management strategies in adult patients at risk for IFALD. Consensus statements related to the provision of lipid emulsions to adults requiring home PN are presented in Table 1 (consensus statements [26] [27] [28] .
Role of Lipids in Adults Requiring Home PN
In patients who require long-term home PN, lipid emulsions are an integral part of nutrition therapy. At a minimum, patients who require home PN should receive IV lipids at a dose sufficient to prevent EFA deficiency (consensus statement 26, Table 1 ).
Lipid Management in Adult Patients at Risk for IFALD
Patients with intestinal failure who require long-term PN are at risk at risk of developing IFALD. IFALD can develop as a consequence of physiological or anatomical abnormalities related to the underlying disease as well as metabolic complications related to PN. 46, 48 PN-related factors include catheter-related sepsis, continuous PN infusion, excessive glucose intake, and the use of soybean oil emulsions at doses higher than 1 g/kg/d. 46, 48, 49 Based on the risk of liver complications, current guidelines indicate that the dose of soybean oil emulsions should not exceed 1 g/kg/d in adults who require long-term (>6 months) home PN. 48 Evidence from clinical trials suggests that the risk of liver complications may be reduced in adult home PN patients by using lipid emulsions containing fish oil. 47, 50 Lipid emulsions containing fish oil offer several potential advantages compared with pure soybean oil emulsions, including reduced ω-6 PUFA and phytosterol content, increased ω-3 PUFA content, and increased amounts of α-tocopherol, an isoform of vitamin E that exhibits strong antioxidant effects. 11, 51, 52 Based on the reduced risk of hepatic injury, lipid emulsions containing fish oil are preferred over lipid emulsions derived exclusively from soybean oil in adult home PN patients at risk for liver complications (consensus statement 27, Table 1 ).
Lipid Management in Adult Patients With Existing IFALD
Limited data are available to guide lipid management strategies in adults with existing IFALD. A recent observational study in adults with soybean oil intolerance receiving home PN showed a reduction in glucose intake and an improvement in measures of liver function after switching from a pure soybean oil emulsion to a mixed lipid emulsion containing fish oil. 53 This suggests that fish-oil containing lipid emulsions may be beneficial in adult home PN patients with IFALD. Additional data from prospective randomized studies are required to evaluate the potential benefit of fishoil containing lipid emulsions in adult patients with IFALD.
Neonates Requiring PN
Neonates have unique nutrition needs owing to factors ranging from high metabolic demands to limited nutrient reserves, and insufficient nutrient intake during the postnatal period can adversely affect long-term growth and neurocognitive development. 2 The article by Deshpande et al 54 in the current supplement reviews the role of lipids in early development and summarizes findings from clinical studies evaluating the effects of various lipid emulsions in neonates requiring PN. Consensus statements related to the provision of lipid emulsions to neonates are presented in Table 1 (consensus statements [29] [30] [31] [32] .
Role of Lipids in Neonates Requiring PN
In neonates who require PN, lipid emulsions are an indispensable component of nutrition therapy. 2 Lipids serve as a concentrated source of energy and EFAs and modulate key metabolic pathways, including inflammatory and immune responses, coagulation, and cell signaling. 2, 5 In preterm neonates, early administration of lipids is associated with improvements in long-term outcomes such as growth and intellectual development. 2 According to current international guidelines, parenteral lipid intake should generally provide 25%-50% of nonprotein energy in fully parenterally fed neonates, and total lipid intake should not exceed 4 g/kg/d. 2 To prevent EFA deficiency, the lipid dose should be sufficient to provide a minimum linoleic acid intake of 0.25 g/kg/d in preterm neonates and 0.1 g/kg/d in term neonates. 2 
Use of Lipid Emulsions Containing Fish Oil in Neonates
Neonates, particularly preterm neonates, are born with limited antioxidative capacity and an immature immune system, making them susceptible to oxidative stress and infection. 55, 56 Lipid emulsions derived exclusively from soybean oil are rich in ω-6 fatty acids and can therefore potentially increase lipid peroxidation, oxidative stress, and inflammation. 2 Composite lipid emulsions containing fish oil have low concentrations of ω-6 fatty acids and high concentrations of the ω-3 fatty acids DHA and EPA and the antioxidant α-tocopherol. 2, 5, 11 Evidence from randomized clinical trials in neonates requiring PN indicate that composite lipid emulsions containing fish oil reduce markers of lipid peroxidation and improve antioxidant status compared with lipid emulsions without fish oil (olive oil/soybean or soybean oil alone). [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] In preterm neonates, evidence from randomized clinical trials demonstrates that composite lipid emulsions containing fish oil offer significant clinical benefits compared with lipid emulsions without fish oil, including reduced risk of bronchopulmonary dysplasia, 67,68 retinopathy of prematurity, [69] [70] [71] and cholestasis, 59, 66, 72 and a shorter duration of mechanical ventilation. 65
Pediatric Patients Requiring PN
The ability to deliver nutrients via PN has markedly improved the prognosis of infants and children with intestinal failure; however, long-term administration of PN may be associated with complications such as IFALD. [73] [74] [75] The article by Goulet et al 76 in the current supplement examines emerging insights regarding the role of lipid emulsions in the management of PN-dependent pediatric patients, with a particular focus on the prevention and treatment of IFALD. Corresponding consensus statements are presented in Table 1 (consensus statements [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] .
Role of Lipids in Pediatric Patients Requiring PN
IV lipid emulsions are an integral component of pediatric PN. According to current international guidelines, parenteral lipid intake in children should be limited to a maximum of 3 g/kg/d and should generally provide 25%-50% of non-protein energy in fully parenterally fed pediatric patients. 2 The most common indications for long-term PN in children are primary digestive diseases causing intestinal failure, including short-bowel syndrome, neuromuscular disorders, and mucosal intestinal diseases. 77, 78 Children with intestinal failure who require long-term PN are at risk for the development of IFALD. 79 The use of soybean lipid emulsions at doses higher than 1 g/kg/d has been identified as a risk factor for IFALD. 11, 74, 79, 80 Potential mechanisms for lipid-mediated liver injury in patients receiving longterm PN with soybean lipid emulsions include increased oxidative stress, phytosterol accumulation, and activation of the reticuloendothelial system. 11, 74 
Lipid Management in Pediatric Patients at Risk for IFALD
Lipid emulsions containing fish oil offer several potential advantages compared with lipid emulsions derived purely from soybean oil, including decreased ω-6 and increased ω-3 PUFA content, higher α-tocopherol levels, and reduced phytosterol content. 2, 5, 11 Studies in PN-dependent infants and children at risk for IFALD have shown that multicomponent lipid emulsions containing fish oil reduce the risk of cholestasis and improve biochemical measures of hepatobiliary function compared with soybean lipid emulsions. [81] [82] [83] 
Lipid Management in Pediatric Patients With Existing IFALD
In PN-dependent children with existing IFALD, cholestasis can be reversed by using fish-oil containing lipid emulsions along with management of other risk factors, especially catheter-related infections and small-intestinal bacterial overgrowth. [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] Pure fish-oil lipid emulsions have been shown to be a valuable short-term rescue treatment in cholestatic pediatric patients who require PN but should not be used as the sole source of lipids over a long period. 2 Based on evidence from clinical studies, administration of a composite lipid emulsion containing fish oil should be considered as first-line treatment for infants and children with existing cholestasis. 90, 91 If elevated levels of conjugated or direct bilirubin (>2 mg/dL [>34 μmol/L]) persist, short-term rescue therapy with a pure fish-oil lipid emulsion should be considered (consensus statement 37, Table 1 ).
Practical Handling Aspects
The safe handling of IV lipid emulsions is an important aspect of PN therapy. The article by Boullata et al 97 in the current supplement reviews the main considerations in the handling of lipid emulsions and offers practical recommendations for the preparation and administration of PN admixtures containing lipid emulsions. Consensus statements related to practical handling aspects are presented in Table 1 (consensus statements [39] [40] [41] [42] [43] .
Minimizing the Risk of Medication Errors
PN is a major source of medication errors, and ≈20%-30% of PN-related medication errors involve IV lipid emulsions. [98] [99] [100] [101] In accordance with major guidelines and consensus recommendations, standardization of the PN process (including prescription, review, preparation, and administration) is recommended to minimize the potential risks associated with PN. [102] [103] [104] [105] Lipid emulsions can be given separately or as part of a total nutrient admixture. Total nutrient admixtures (including commercial multi-chamber bags and pharmacy compounded bags) reduce line manipulations, infection risk, and cost compared with multi-bottle systems. 106 In addition, commercial multi-chamber PN products are associated with fewer medication errors. 107 When compounding is necessary, clinicians should ensure that the prescribed formulation is reviewed and prepared under the supervision of a pharmacist with expertise in compounding PN admixtures (consensus statement 40, Table 1 ).
Prevention of Lipid Peroxidation and Contamination
IV lipid emulsions with a high PUFA content are particularly prone to lipid peroxidation, which can lead to cellular damage and liver injury. Data from in vitro studies suggest that concomitant administration of multivitamins containing ascorbic acid with an IV lipid emulsion via lightprotected tubing is an effective method for preventing lipid peroxidation and limiting vitamin loss. 2 Repackaging of IV lipid emulsions, a practice typically used to reduce the volume of lipid infusions for neonatal and pediatric patients, increases the risk of contamination. [108] [109] [110] [111] The risks of contamination should be weighed against the benefits of smaller lipid volumes. 112 Repackaging should be avoided if possible; if repackaging is performed, it should be under aseptic conditions and the IV lipid emulsion should be used within 12 hours (consensus statements 41 and 43, Table 1 ).
To prevent the risks associated with infusion of microprecipitates and particulate matter, guidelines from the United States and the United Kingdom recommend the use of a filter for PN admixtures. 113, 114 For lipid-containing emulsions, 1.2-μm filters should be used. 113, [115] [116] [117] However, the routine use of in-line filters is not widespread in Europe, Japan, or Australia. 113, [118] [119] [120] In several countries, guidelines recommend the use of in-line filters in at-risk groups such as neonates, children, immunocompromised patients, and patients who require intensive PN therapy, but not in all patients. 113, 115, 116 For instance, European guidelines on pediatric PN state that PN admixtures may be administered through a terminal filter. 117
Pharmacoeconomic Considerations
The management of patients who require PN represents a substantial source of healthcare resource consumption. Thus, the cost-effectiveness of various IV lipid emulsions is an important consideration when assessing therapeutic options, 121, 122 and so these pharmacoeconomic aspects have also been reviewed in this supplement. 123 Discrete-event simulation models that incorporate evidence-based clinical data and cost estimates derived from local sources are recognized as a useful method for evaluating health economic outcomes. 124, 125 Pharmacoeconomic evaluations comparing lipid emulsions containing ω-3 fatty acids with standard lipid emulsions in critically ill and surgical populations have shown that using IV lipid emulsions containing ω-3 fatty acids is a cost-effective strategy in patients who require PN. 121, 122, 126 According to findings from discrete-event simulation models using clinical outcomes data from meta-analyses and cost data from regional sources as model inputs, in critically ill and surgical patients who require PN, the acquisition cost of ω-3 fatty-acid containing lipid emulsions is more than offset by the cost savings from reductions in length of hospital and/or ICU stay and less antibiotic use. 121, 122, 126 Additional studies may be beneficial to evaluate the potential pharmacoeconomic benefits of lipid emulsions containing ω-3 fatty acids in other patient populations.
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